Business Wire- ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the closing of a $36 million Series C financing, including existing convertible notes.
Recent Posts
Meet the Executive: Tal Heppenstall, President of UPMC Enterprises
It’s been five years since UPMC rebranded its long-standing work on health care innovation and …
Read More →
RxAnte launches technology-enabled comprehensive pharmacy service for medically complex and vulnerable Medicare members
RxAnte, a UPMC Enterprises portfolio company, recently developed and launched a transformative direct-to-member service that …
Read More →